• HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
Sunday, November 9, 2025
BIOENGINEER.ORG
No Result
View All Result
  • Login
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
No Result
View All Result
Bioengineer.org
No Result
View All Result
Home NEWS Science News Biology

‘Self-sabotage’ prevents immune protection against malaria

Bioengineer by Bioengineer
January 24, 2018
in Biology, Science News
Reading Time: 3 mins read
0
Share on FacebookShare on TwitterShare on LinkedinShare on RedditShare on Telegram
IMAGE

IMAGE: Australian scientists have for the first time revealed how malaria parasites cause an inflammatory reaction that sabotages our body's ability to protect itself against the disease.

Dr. Axel Kallies (left) and…

Credit: Walter and Eliza Hall Institute of Medical Research

Australian scientists have for the first time revealed how malaria parasites cause an inflammatory reaction that sabotages our body's ability to protect itself against the disease.

The discovery opens up the possibility of improving new or existing malaria vaccines by boosting key immune cells needed for long-lasting immunity. This could even include vaccines that have previously been ineffective in clinical trials.

Researchers from Melbourne's Walter and Eliza Hall Institute discovered that the same inflammatory molecules that drive the immune response in clinical and severe malaria also prevent the body from developing protective antibodies against the parasite.

Dr Diana Hansen, Dr Axel Kallies and Dr Victoria Ryg-Cornejo led a research team that examined how the immune system responded to malaria infection caused by Plasmodium falciparum. The findings were published today in the journal Cell Reports.

Dr Hansen said it was the first time scientists had pinpointed why the immune system fails to develop immunity during malaria infection.

"With many infections, a single exposure to the pathogen is enough to induce production of antibodies that will protect you for the rest of your life," Dr Hansen said. "However with malaria it can take up to 20 years for someone to build up sufficient immunity to be protected. During that time people exposed to malaria are susceptible to reinfection and become sick many times, as well as spreading the disease."

Malaria has traditionally been difficult to manage because the body is not good at developing long-lasting immunity to the parasite, which has hampered vaccine development, Dr Hansen said.

"This was complicated by the fact that we didn't know whether it was the malaria parasite itself or the inflammatory reaction to malaria that was actually inhibiting the ability to develop protective immunity.

"We have now shown that it was a double-edged sword: the strong inflammatory reaction that accompanies and in fact drives severe clinical malaria is also responsible for silencing the key immune cells needed for long-term protection against the parasite."

Dr Kallies said inflammatory molecules released by the body to fight the infection were preventing protective antibodies from being made. "Long-term immunity to malaria and other pathogens requires antibody responses," he said.

"Specialised immune cells called helper T cells join forces with B cells to generate these protective antibodies. However, we showed that during malaria infection critical inflammatory molecules actually arrest development of helper T cells and therefore the B cells don't get the necessary instructions to make antibodies."

Malaria is one of the most serious human infectious diseases, with about 250 million clinical cases each year. Children are particularly susceptible to severe malaria because they have little or no immunity to the parasite. Severe malaria causes symptoms including anaemia, breathing difficulties, kidney failure and coma, and can quickly lead to death.

Dr Hansen said the findings could lead to new avenues in the search for effective malaria vaccines. "This research opens the door to therapeutic approaches to accelerate development of protective immunity to malaria and improve efficacy of malaria vaccines," she said.

"Until now, malaria vaccines have had disappointing results. We can now see a way of improving these responses, by tailoring or augmenting the vaccine to boost development of helper T cells that will enable the body to make protective antibodies that target the malaria parasites."

###

The research was supported by the National Health and Medical Research Council, the Australian Research Council, the Sylvia and Charles Viertel Charitable Foundation and the Victorian Government Operational Infrastructure Support Program.

Share12Tweet8Share2ShareShareShare2

Related Posts

Major Global Study Finds Beta-Blockers Unnecessary for Post-Infarction Patients with Normal Cardiac Function

November 9, 2025
blank

Simulating Cochlear Implant Sound for Hearing Experience

November 9, 2025

Stenting All Blocked Arteries Lowers Cardiovascular Death Risk Compared to Treating Only the Culprit Artery in Heart Attack Patients

November 9, 2025

Targeted Vitamin D3 Supplementation Halves Risk of Repeat Heart Attacks, New Intermountain Health Study Reveals

November 9, 2025
Please login to join discussion

POPULAR NEWS

  • blank

    Stinkbug Leg Organ Hosts Symbiotic Fungi That Protect Eggs from Parasitic Wasps

    315 shares
    Share 126 Tweet 79
  • ESMO 2025: mRNA COVID Vaccines Enhance Efficacy of Cancer Immunotherapy

    207 shares
    Share 83 Tweet 52
  • New Study Suggests ALS and MS May Stem from Common Environmental Factor

    139 shares
    Share 56 Tweet 35
  • Sperm MicroRNAs: Crucial Mediators of Paternal Exercise Capacity Transmission

    1303 shares
    Share 520 Tweet 325

About

We bring you the latest biotechnology news from best research centers and universities around the world. Check our website.

Follow us

Recent News

Major Global Study Finds Beta-Blockers Unnecessary for Post-Infarction Patients with Normal Cardiac Function

Simulating Cochlear Implant Sound for Hearing Experience

Stenting All Blocked Arteries Lowers Cardiovascular Death Risk Compared to Treating Only the Culprit Artery in Heart Attack Patients

Subscribe to Blog via Email

Enter your email address to subscribe to this blog and receive notifications of new posts by email.

Join 69 other subscribers
  • Contact Us

Bioengineer.org © Copyright 2023 All Rights Reserved.

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In
No Result
View All Result
  • Homepages
    • Home Page 1
    • Home Page 2
  • News
  • National
  • Business
  • Health
  • Lifestyle
  • Science

Bioengineer.org © Copyright 2023 All Rights Reserved.